Having de facto perpetual monopolies of originator biologics is not sustainable in an optimally functioning market. A balance needs to be struck between maintaining incentives for R&D of innovator biologics, allowing for biosimilar entry, and improving access through rational payer benefit design.
Federal Appeals Court Blocks Launch Of Biosimilar Erelzi
